Every reporter Jin Zhe Every trainee reporter Lin Zichen Every editor Zhang Haini
On the evening of August 4, Xinhua News Agency issued a document stating that medical “increasing needles”, that is, injections of growth hormone, have signs of abuse, which will bring health risks to users. On the 5th, Changchun High-tech (000661, SZ), the major shareholder of the domestic growth hormone leader Jinsai Pharmaceutical, plummeted at the opening.
In response, Changchun High-tech responded that there is no abuse of growth hormone in the company. In addition to growth hormone, Jinsai Pharmaceutical also has a layout in neurological diseases (alzheimer’s disease, etc.), gynecology and andrology. In the future, it will also focus on the production of hormones. Towards diversification. Regarding the future development prospects of Changchun Hi-tech, He Shan, research director of Senrui Investment, believes that the current P/E ratio of Changchun Hi-tech has dropped to about 30 times, and the valuation level is still attractive. In addition, the company still has an adult indication and pediatric drug platform. , There is still room for imagination in development.
Copyright Notice
1This article is the original work of “Daily Economic News”.
2
Without the authorization of “Daily Economic News”, it may not be used in any way, including but not limited to reprinting, extracting, copying or creating mirror images, etc., offenders must be investigated.
3Copyright cooperation telephone: 021-60900099.